M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - FRA:M12 - DE000A0STSQ8 - Common Stock
14.3 EUR
-0.08 (-0.56%)
Overall M12 gets a fundamental rating of 6 out of 10. We evaluated M12 against 30 industry peers in the Health Care Providers & Services industry. M12 is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. M12 has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
In the past year M12 had a positive cash flow from operations.
M12 had positive earnings in each of the past 5 years.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
M12 has a Return On Assets of 8.73%. This is amongst the best in the industry. M12 outperforms 96.67% of its industry peers.
M12's Return On Equity of 15.03% is fine compared to the rest of the industry. M12 outperforms 73.33% of its industry peers.
M12 has a Return On Invested Capital of 13.44%. This is amongst the best in the industry. M12 outperforms 86.67% of its industry peers.
M12 had an Average Return On Invested Capital over the past 3 years of 7.72%. This is in line with the industry average of 6.66%.
The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
M12's Profit Margin of 5.00% is amongst the best of the industry. M12 outperforms 83.33% of its industry peers.
M12's Profit Margin has declined in the last couple of years.
The Operating Margin of M12 (8.52%) is better than 76.67% of its industry peers.
M12's Operating Margin has declined in the last couple of years.
M12 has a Gross Margin of 19.29%. This is in the lower half of the industry: M12 underperforms 60.00% of its industry peers.
In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
M12 has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
M12 has less shares outstanding than it did 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, M12 has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.20 indicates that M12 is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.20, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12 has a Debt to FCF ratio of 0.70. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
M12 has a Debt to Equity ratio of 0.05. This is amongst the best in the industry. M12 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.2 |
ROIC/WACC1.86
WACC7.22%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of M12 (2.06) is better than 90.00% of its industry peers.
A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, M12 is in the better half of the industry, outperforming 76.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.36% over the past year.
The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
The Revenue has been growing slightly by 6.52% in the past year.
The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
The Earnings Per Share is expected to grow by 19.18% on average over the next years. This is quite good.
Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 8.24% on average per year.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
M12 is valuated correctly with a Price/Earnings ratio of 15.21.
73.33% of the companies in the same industry are more expensive than M12, based on the Price/Earnings ratio.
M12's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.06.
Based on the Price/Forward Earnings ratio of 12.33, the valuation of M12 can be described as correct.
M12's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. M12 is cheaper than 63.33% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 32.73, M12 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.21 | ||
| Fwd PE | 12.33 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M12 is cheaper than 80.00% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 73.33% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.52 | ||
| EV/EBITDA | 6.81 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
A more expensive valuation may be justified as M12's earnings are expected to grow with 19.18% in the coming years.
PEG (NY)2.93
PEG (5Y)1.91
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.48%.
M12's Dividend Yield is rather good when compared to the industry average which is at 2.55. M12 pays more dividend than 96.67% of the companies in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.48% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (11/7/2025, 7:00:00 PM)
14.3
-0.08 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.8%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap280.85M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (89.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.48% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.21 | ||
| Fwd PE | 12.33 | ||
| P/S | 0.79 | ||
| P/FCF | 10.52 | ||
| P/OCF | 10.39 | ||
| P/B | 2.38 | ||
| P/tB | 10.23 | ||
| EV/EBITDA | 6.81 |
EPS(TTM)0.94
EY6.57%
EPS(NY)1.16
Fwd EY8.11%
FCF(TTM)1.36
FCFY9.51%
OCF(TTM)1.38
OCFY9.63%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)2.93
PEG (5Y)1.91
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.2 |
F-Score9
WACC7.22%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year31.44%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 7 / 10 to M12.DE.
Can you provide the valuation status for M1 KLINIKEN AG?
ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
What are the PE and PB ratios of M1 KLINIKEN AG (M12.DE) stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 15.21 and the Price/Book (PB) ratio is 2.38.